147 related articles for article (PubMed ID: 20863554)
1. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.
Cella D; Huang H; Homesley HD; Montag A; Salani R; De Geest K; Lee R; Spirtos NM
Gynecol Oncol; 2010 Dec; 119(3):538-42. PubMed ID: 20863554
[TBL] [Abstract][Full Text] [Related]
2. [A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].
Honma H; Sagae S; Terasawa K; Tanaka R; Chida M; Mizumoto H; Ishioka S; Saito T; Kudo R
Gan To Kagaku Ryoho; 2004 Apr; 31(4):549-53. PubMed ID: 15114698
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
4. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study.
Dimopoulos MA; Papadimitriou CA; Georgoulias V; Moulopoulos LA; Aravantinos G; Gika D; Karpathios S; Stamatelopoulos S
Gynecol Oncol; 2000 Jul; 78(1):52-7. PubMed ID: 10873410
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
Fleming GF; Brunetto VL; Cella D; Look KY; Reid GC; Munkarah AR; Kline R; Burger RA; Goodman A; Burks RT
J Clin Oncol; 2004 Jun; 22(11):2159-66. PubMed ID: 15169803
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
9. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.
Thigpen T; Vance RB; Khansur T
Semin Oncol; 1995 Oct; 22(5 Suppl 12):67-75. PubMed ID: 7481864
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Aravantinos G; Fountzilas G; Bamias A; Grimani I; Rizos S; Kalofonos HP; Skarlos DV; Economopoulos T; Kosmidis PA; Stathopoulos GP; Briasoulis E; Pectasides D; Samantas E; Timotheadou E; Papadimitriou C; Papanikolaou A; Onyenadum A; Papakostas P; Bafaloukos D; Dimopoulos MA;
Eur J Cancer; 2008 Oct; 44(15):2169-77. PubMed ID: 18691879
[TBL] [Abstract][Full Text] [Related]
11. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
[TBL] [Abstract][Full Text] [Related]
12. A patient with granulocyte-colony stimulating factor-producing endometrial cancer who responded to high-dose cisplatin, cyclophosphamide and adriamycin.
Hada T; Mikami M; Kuwabara Y; Tanaka K; Ishikawa M; Komiyama S; Hirose T
Eur J Obstet Gynecol Reprod Biol; 2004 Oct; 116(2):242-3. PubMed ID: 15358478
[No Abstract] [Full Text] [Related]
13. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.
Sehouli J; Koensgen D; Oskay-Ozcelik G; Mustea A
Crit Rev Oncol Hematol; 2008 Sep; 67(3):204-12. PubMed ID: 18407513
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.
Homesley HD; Filiaci V; Gibbons SK; Long HJ; Cella D; Spirtos NM; Morris RT; DeGeest K; Lee R; Montag A
Gynecol Oncol; 2009 Mar; 112(3):543-52. PubMed ID: 19108877
[TBL] [Abstract][Full Text] [Related]
16. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
Shea T; Graham M; Bernard S; Steagall A; Wiley J; Serody J; Brecher M; Bentley S; Johnston C; Vaisman A
Semin Oncol; 1995 Oct; 22(5 Suppl 12):80-5. PubMed ID: 7481867
[TBL] [Abstract][Full Text] [Related]
17. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.
Fanning J; Colgrove M; Phibbs G
Gynecol Oncol; 2000 Oct; 79(1):97-100. PubMed ID: 11006039
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
20. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
Chaudhry V; Rowinsky EK; Sartorius SE; Donehower RC; Cornblath DR
Ann Neurol; 1994 Mar; 35(3):304-11. PubMed ID: 7907208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
